Skip to main content
Erschienen in: Strahlentherapie und Onkologie 11/2016

11.07.2016 | Original Article

Novel technique for high-precision stereotactic irradiation of mouse brains

verfasst von: J. Hartmann, J. Wölfelschneider, C. Stache, R. Buslei, A. Derer, M. Schwarz, T. Bäuerle, R. Fietkau, U. S. Gaipl, C. Bert, A. Hölsken, B. Frey

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Small animal irradiation systems were developed for preclinical evaluation of tumor therapy closely resembling the clinical situation. Mostly only clinical LINACs are available, so protocols for small animal partial body irradiation using a conventional clinical system are essential. This study defines a protocol for conformal brain tumor irradiations in mice.

Materials and methods

CT and MRI images were used to demarcate the target volume and organs at risk. Three 6 MV photon beams were planned for a total dose of 10 fractions of 1.8 Gy. The mouse position in a dedicated applicator was verified by an X‑ray patient positioning system before each irradiation. Dosimetric verifications (using ionization chambers and films) were performed. Irradiation-induced DNA damage was analyzed to verify the treatment effects on the cellular level.

Results

The defined treatment protocol and the applied fractionation scheme were feasible. The in-house developed applicator was suitable for individual positioning at submillimeter accuracy of anesthetized mice during irradiation, altogether performed in less than 10 min. All mice tolerated the treatment well. Measured dose values perfectly matched the nominal values from treatment planning. Cellular response was restricted to the target volume.

Conclusion

Clinical LINAC-based irradiations of mice offer the potential to treat orthotopic tumors conformably. Especially with respect to lateral penumbra, dedicated small animal irradiation systems exceed the clinical LINAC solution.
Literatur
4.
Zurück zum Zitat Derer A, Frey B, Fietkau R, Gaipl US (2015) Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. doi:10.1007/s00262-015-1771-8 PubMed Derer A, Frey B, Fietkau R, Gaipl US (2015) Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother. doi:10.​1007/​s00262-015-1771-8 PubMed
5.
Zurück zum Zitat De Ryck T, Van Impe A, Vanhoecke BW, Heyerick A, Vakaet L, De Neve W, Muller D, Schmidt M, Dorr W, Bracke ME (2015) 8‑prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis : cell culture and murine model. Strahlenther Onkol 191(5):429–436. doi:10.1007/s00066-014-0782-2 CrossRefPubMed De Ryck T, Van Impe A, Vanhoecke BW, Heyerick A, Vakaet L, De Neve W, Muller D, Schmidt M, Dorr W, Bracke ME (2015) 8‑prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis : cell culture and murine model. Strahlenther Onkol 191(5):429–436. doi:10.​1007/​s00066-014-0782-2 CrossRefPubMed
6.
Zurück zum Zitat Muth C, Rubner Y, Semrau S, Ruhle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US (2015) Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin. Strahlenther Onkol. doi:10.1007/s00066-015-0926-z PubMed Muth C, Rubner Y, Semrau S, Ruhle PF, Frey B, Strnad A, Buslei R, Fietkau R, Gaipl US (2015) Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin. Strahlenther Onkol. doi:10.​1007/​s00066-015-0926-z PubMed
7.
Zurück zum Zitat Clarkson R, Lindsay PE, Ansell S, Wilson G, Jelveh S, Hill RP, Jaffray DA (2011) Characterization of image quality and image-guidance performance of a preclinical microirradiator. Med Phys 38(2):845–856CrossRefPubMedPubMedCentral Clarkson R, Lindsay PE, Ansell S, Wilson G, Jelveh S, Hill RP, Jaffray DA (2011) Characterization of image quality and image-guidance performance of a preclinical microirradiator. Med Phys 38(2):845–856CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Wong J, Armour E, Kazanzides P, Iordachita U, Tryggestad E, Deng H, Matinfar M, Kennedy C, Liu ZJ, Chan T, Gray O, Verhaegen F, McNutt T, Ford E, DeWeese TL (2008) High-resolution, small animal radiation research platform with X‑ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 71(5):1591–1599. doi:10.1016/j.ijrobp.2008.04.025 CrossRefPubMedPubMedCentral Wong J, Armour E, Kazanzides P, Iordachita U, Tryggestad E, Deng H, Matinfar M, Kennedy C, Liu ZJ, Chan T, Gray O, Verhaegen F, McNutt T, Ford E, DeWeese TL (2008) High-resolution, small animal radiation research platform with X‑ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys 71(5):1591–1599. doi:10.​1016/​j.​ijrobp.​2008.​04.​025 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Tillner F, Hietschold V, Khaless A, Pawelke J, Thute P, Enghardt W (2010) Characterization and optimization of the imaging and dosimetric properties of a image-guided precision irradiation device for small animals. Strahlenther Onkol 186:105–105 Tillner F, Hietschold V, Khaless A, Pawelke J, Thute P, Enghardt W (2010) Characterization and optimization of the imaging and dosimetric properties of a image-guided precision irradiation device for small animals. Strahlenther Onkol 186:105–105
11.
Zurück zum Zitat Felix MC, Fleckenstein J, Kirschner S, Hartmann L, Wenz F, Brockmann MA, Glatting G, Giordano FA (2015) Image-guided radiotherapy using a modified industrial Micro-CT for preclinical applications. PLoS ONE 10(5):11. doi:10.1371/journal.pone.0126246 CrossRef Felix MC, Fleckenstein J, Kirschner S, Hartmann L, Wenz F, Brockmann MA, Glatting G, Giordano FA (2015) Image-guided radiotherapy using a modified industrial Micro-CT for preclinical applications. PLoS ONE 10(5):11. doi:10.​1371/​journal.​pone.​0126246 CrossRef
17.
Zurück zum Zitat Stache C, Holsken A, Schlaffer SM, Hess A, Metzler M, Frey B, Fahlbusch R, Flitsch J, Buchfelder M, Buslei R (2015) Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathol 25(1):1–10. doi:10.1111/bpa.12148 CrossRefPubMed Stache C, Holsken A, Schlaffer SM, Hess A, Metzler M, Frey B, Fahlbusch R, Flitsch J, Buchfelder M, Buslei R (2015) Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathol 25(1):1–10. doi:10.​1111/​bpa.​12148 CrossRefPubMed
20.
Zurück zum Zitat Stache C, Holsken A, Fahlbusch R, Flitsch J, Schlaffer SM, Buchfelder M, Buslei R (2014) Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth. Neuro-oncology 16(2):256–264. doi:10.1093/neuonc/not195 CrossRefPubMed Stache C, Holsken A, Fahlbusch R, Flitsch J, Schlaffer SM, Buchfelder M, Buslei R (2014) Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth. Neuro-oncology 16(2):256–264. doi:10.​1093/​neuonc/​not195 CrossRefPubMed
21.
Zurück zum Zitat Low DA, Mutic S, Dempsey JF, Gerber RL, Bosch WR, Perez CA, Purdy JA (1998) Quantitative dosimetric verification of an IMRT planning and delivery system. Radiother Oncol 49(3):305–316CrossRefPubMed Low DA, Mutic S, Dempsey JF, Gerber RL, Bosch WR, Perez CA, Purdy JA (1998) Quantitative dosimetric verification of an IMRT planning and delivery system. Radiother Oncol 49(3):305–316CrossRefPubMed
25.
Zurück zum Zitat Bache ST, Juang T, Belley MD, Koontz BF, Adamovics J, Yoshizumi TT, Kirsch DG, Oldham M (2015) Investigating the accuracy of microstereotactic-body-radiotherapy utilizing anatomically accurate 3D printed rodent-morphic dosimeters. Med Phys 42(2):846–855. doi:10.1118/1.4905489 CrossRefPubMedPubMedCentral Bache ST, Juang T, Belley MD, Koontz BF, Adamovics J, Yoshizumi TT, Kirsch DG, Oldham M (2015) Investigating the accuracy of microstereotactic-body-radiotherapy utilizing anatomically accurate 3D printed rodent-morphic dosimeters. Med Phys 42(2):846–855. doi:10.​1118/​1.​4905489 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Welch D, Harken AD, Randers-Pehrson G, Brenner DJ (2015) Construction of mouse phantoms from segmented CT scan data for radiation dosimetry studies. Phys Med Biol 60:3589–3598CrossRefPubMedPubMedCentral Welch D, Harken AD, Randers-Pehrson G, Brenner DJ (2015) Construction of mouse phantoms from segmented CT scan data for radiation dosimetry studies. Phys Med Biol 60:3589–3598CrossRefPubMedPubMedCentral
Metadaten
Titel
Novel technique for high-precision stereotactic irradiation of mouse brains
verfasst von
J. Hartmann
J. Wölfelschneider
C. Stache
R. Buslei
A. Derer
M. Schwarz
T. Bäuerle
R. Fietkau
U. S. Gaipl
C. Bert
A. Hölsken
B. Frey
Publikationsdatum
11.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 11/2016
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-016-1014-8

Weitere Artikel der Ausgabe 11/2016

Strahlentherapie und Onkologie 11/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.